Tapentadol is partially metabolized by the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medication that enrich or repress the exercise/expression of one or more of those enzymes, as well as with substrates of these enzymes (because of competition to the enzyme); some enzyme mediators/substrates call https://sandraq948aeh8.newsbloger.com/profile